GSK PLC

GSK PLC prepares to report Q4 earnings on Oct 28, with analysts projecting EPS of £0.505, while unveiling an $800 M U.S. expansion to boost vaccine capacity and create jobs.

GSK invests $800 million in a new Pennsylvania hub and partners with AI firm Chai Discovery, boosting U.S. manufacturing, jobs, and drug‑discovery speed.

GSK’s lung‑cancer breakthrough fuels a share rally, with Jideytro & Ris‑Rez Phase III wins and a strategic German plant closure boosting investor confidence.

GSK secures Japan approval for Shingrix prefilled syringe, boosting shingles vaccine reach and investor confidence in its global growth strategy.

GSK PLC’s $110 m Phase‑1 oncology acquisition from Hutchmed unlocks a potent small‑molecule cancer drug, boosting its pipeline, investor upside and future growth potential.

GSK lands a $1.3bn deal for KRAS‑EGFR antibody‑drug conjugate HMPL‑A830, boosting its oncology pipeline and global reach with a high‑potency first‑in‑class therapy.

GSK launches phase‑III trial for its dual‑target mRNA flu vaccine, boasting stronger immune responses than licensed shots and positioning a potential market shift.

GSK stock nears a 52‑week peak amid looming patent expirations; discover how its diverse pipeline may cushion margin pressure and drive future growth.

GSK secures US FDA priority review for Jemperli and Japan’s first approval of Hibsago, boosting its cancer and hepatitis pipeline amid active executive share sales.

GSK’s phase‑III lung‑cancer win with Riz‑Rez and new China partnerships boost its oncology pipeline and share price, while shedding Alector to focus on high‑impact therapies.